Serum and Aqueous Concentrations of Inflammatory Markers in Diabetic Macular Edema

References

• World Health Organization. Global data on visual impairments, 2010. Geneva: WHO. 2012. Available from: http://www.who.int/blindness/globaldatafinalforweb.pdf
   Google Scholar
• Qian H, Ripps H. Neurovascular interaction and the pathophysiology of diabetic retinopathy. Exp Diabetes Res. 2011;2011:Article ID 693426
   Google Scholar
• Bhagat N, Grigorian RA, Tutela A, et al. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol. 2009;54:1–32
   PubMed Web of Science ®Google Scholar
• Lang GE. Diabetic macular edema. Ophthalmologica. 2012;227:21–29
   PubMed Web of Science ®Google Scholar
• Cunha-Vaz J, Bernardes R, Lobo C. Blood-retinal barrier. Eur J Ophthalmol. 2011;21:S3–S9
   PubMed Web of Science ®Google Scholar
• Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin Eye Res. 2011;30:343–358
   PubMed Web of Science ®Google Scholar
• Temelkova-Kurktschiev T, Henkel E, Koehler C, et al. Subclinical inflammation in newly detected type II diabetes and impaired glucose tolerance. Diabetologia. 2002;45:151
   PubMed Web of Science ®Google Scholar
• Powell ED, Field RA. Diabetic retinopathy in rheumatoid arthritis. Lancet. 1964;2:17–18
   PubMed Web of Science ®Google Scholar
• Joussen AM, Doehmen S, Le ML, et al. TNF-alpha mediated apoptosis plays an important role in the development of early diabetic retinopathy and long-term histopathological alterations. Mol Vis. 2009;15:1418–1428
   PubMed Web of Science ®Google Scholar
• Joussen AM, Poulaki V, Mitsiades N, et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J. 2002;16:438–440
   PubMed Web of Science ®Google Scholar
• Sfikakis PP, Markomichelakis N, Theodossiadis GP, et al. Regression of sight-threatening macular edema in type 2 diabetes following treatment with the anti-tumor necrosis factor monoclonal antibody infliximab. Diabetes Care. 2005;28:445–447
   PubMed Web of Science ®Google Scholar
• Sfikakis PP, Grigoropoulos V, Emfietzoglou I, et al. Infliximab for diabetic macular edema refractory to laser photocoagulation: a randomized, double-blind, placebo-controlled, crossover, 32-week study. Diabetes Care. 2010;33:1523–1528
   PubMed Web of Science ®Google Scholar
• Early Treatment Diabetic Retinopathy Study research group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study, report number 1. Arch Ophthalmol. 1985;103:1796–1806
   PubMed Web of Science ®Google Scholar
• Stitt AW. AGEs and diabetic retinopathy. Invest Ophthalmol Vis Sci. 2010;51:4867–4874
   PubMed Web of Science ®Google Scholar
• Mugabo Y, Li L, Renier G. The connection between C-reactive protein (CRP) and diabetic vasculopathy. Focus on preclinical findings. Curr Diabetes Rev. 2010;6:27–34
   PubMedGoogle Scholar
• Nakamura K, Yamagishi S, Adachi H, et al. Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes. Mol Med. 2007;13(3–4):185–189
   PubMed Web of Science ®Google Scholar
• Tan KC, Chow WS, Tam S, et al. Association between acute-phase reactants and advanced glycation end products in type 2 diabetes. Diabetes Care. 2004;27:223–228
   PubMed Web of Science ®Google Scholar
• Huang H, Gandhi JK, Zhong X, et al. TNF-alpha is required for late BRB breakdown in diabetic retinopathy, and its inhibition prevents leukostasis and protects vessels and neurons from apoptosis. Invest Ophthalmol Vis Sci. 2011;52:1336–1344
   PubMed Web of Science ®Google Scholar
• Aveleira CA, Lin CM, Abcouwer SF, et al. TNF-α signals through PKCζ/NF-κB to alter the tight junction complex and increase retinal endothelial cell permeability. Diabetes. 2010;59:2872–2882
   PubMed Web of Science ®Google Scholar
• Klein BE, Knudtson MD, Tsai MY, et al. The relation of markers of inflammation and endothelial dysfunction to the prevalence and progression of diabetic retinopathy: Wisconsin epidemiologic study of diabetic retinopathy. Arch Ophthalmol. 2009;127:1175–1182
   PubMed Web of Science ®Google Scholar
• Maier R, Weger M, Haller-Schober EM, et al. Multiplex bead analysis of vitreous and serum concentrations of inflammatory and proangiogenic factors in diabetic patients. Mol Vis. 2008;14:637–643
   PubMed Web of Science ®Google Scholar
• Koleva-Georgieva DN, Sivkova NP, Terzieva D. Serum inflammatory cytokines IL-1beta, IL-6, TNF-alpha and VEGF have influence on the development of diabetic retinopathy. Folia Med (Plovdiv). 2011;53:44–50
   PubMedGoogle Scholar
• Adamiec-Mroczek J, Oficjalska-Młynczak J, Misiuk-Hojło M. Roles of endothelin-1 and selected proinflammatory cytokines in the pathogenesis of proliferative diabetic retinopathy: analysis of vitreous samples. Cytokine. 2010;49:269–274
   PubMed Web of Science ®Google Scholar
• Meleth AD, Agrón E, Chan CC, et al. Serum inflammatory markers in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2005;46:4295–4301
   PubMed Web of Science ®Google Scholar
• Doganay S, Evereklioglu C, Er H, et al. Comparison of serum NO, TNF-alpha, IL-1beta, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus. Eye (Lond). 2002;16:163–170
   PubMed Web of Science ®Google Scholar
• Demircan N, Safran BG, Soylu M, et al. Determination of vitreous interleukin-1(IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye (Lond). 2006;20:1366–1369
   PubMed Web of Science ®Google Scholar
• Gustavsson C, Agardh CD, Agardh E. Profile of intraocular tumour necrosis factor-α and interleukin-6 in diabetic subjects with different degrees of diabetic retinopathy. Acta Ophthalmol. 2013;91:445–452
   PubMed Web of Science ®Google Scholar
• Oh IK, Kim SW, Oh J, et al. Inflammatory and angiogenic factors in the aqueous humor and the relationship to diabetic retinopathy. Curr Eye Res. 2010;35:1116–1127
   PubMed Web of Science ®Google Scholar
• Ozturk BT, Bozkurt B, Kerimoglu H, et al. Effect of serum cytokines and VEGF levels on diabetic retinopathy and macular thickness. Mol Vis. 2009;15:1906–1914
   PubMed Web of Science ®Google Scholar
• Funatsu H, Noma H, Mimura T, et al. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology. 2009;116:73–79
   PubMed Web of Science ®Google Scholar
• Cheung CM, Vania M, Ang M, et al. Comparison of aqueous humor cytokine and chemokine levels in diabetic patients with and without retinopathy. Mol Vis. 2012;18:830–837
   PubMed Web of Science ®Google Scholar
• Jonas JB, Jonas RA, Neumaier M, et al. Cytokine concentration in aqueous humor of eyes with diabetic macular edema. Retina. 2012;32:2150–2157
   PubMed Web of Science ®Google Scholar
• Burgos R, Simó R, Audí L, et al. Vitreous levels of vascular endothelial growth factor are not influenced by its serum concentrations in diabetic retinopathy. Diabetologia. 1997;40:1107–1109
   PubMed Web of Science ®Google Scholar